Avadel Pharmaceuticals plc ADR (NASDAQ:AVDL) saw an upside of 2.35% to close Friday at $11.34 after adding $0.26 on the day. The 5-day average trading volume is 553,680 shares of the company’s common stock. It has gained $12.30 in the past week and touched a new high 1 time within the past 5 days. An average of 461,465 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 622,878.
AVDL’s 1-month performance is -18.42% or -$2.17 on its low of $10.74 reached on 09/21/23. The company’s shares have touched a 52-week low of $4.61 and high of $16.85, with the stock’s rally to the 52-week high happening on 07/17/23. YTD, AVDL has achieved 58.38% or $4.18 and has reached a new high 28 times. However, the current price is down -32.70% from the 52-week high price.
Insider Transactions
AVDL stock investors last saw insider trading activity on Aug 14.McCamish Mark Anthony (Director) most recently sold 28,975 shares at $14.93 per share on Aug 11. This transaction cost the insider $432,614.
Valuation Metrics
AVDL stock has a beta of 1.50. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 675.26 while the price-to-book (PB) in the most recent quarter is 7.49.
Avadel Pharmaceuticals plc ADR’s quick ratio for the period ended June 29 was 3.30, with the current ratio over the same period at 3.32. In terms of profitability, the gross margin trailing 12 months is -47.86%.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income grew 1.54% to -$64.43 million, while revenue of -$30.78 million was 52.23% off the previous quarter. Analysts expected AVDL to announce -$0.38 per share in earnings in its latest quarter, but it posted -$0.83, representing a -118.40% surprise. EBITDA for the quarter stood at more than -$48.94 million. AVDL stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 57.78 million, with total debt at $22.12 million. Shareholders hold equity totaling $89.37 million.
Let’s look briefly at Avadel Pharmaceuticals plc ADR (AVDL) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 22 September was 27.47% to suggest the stock is trending oversold, with historical volatility in this time period at 32.31%.
The stock’s 5-day moving average is $11.43, reflecting a -7.58% or -$0.93 change from its current price. AVDL is currently trading -17.83% above its 20-day SMA, -3.32% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -26.65% and SMA200 by+29.60%.
Stochastic %K and %D was 11.70% and 8.50% and the average true range (ATR) pointed at 0.58. The RSI (14) points at 31.47%, while the 14-day stochastic is at 21.74% with the period’s ATR at 0.61. The stock’s 9-day MACD Oscillator is pointing at -0.61 and -1.02 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Avadel Pharmaceuticals plc ADR (NASDAQ: AVDL), Jefferies upgraded it to a Buy rating. They previously had a Hold rating on the stock. Analysts offering their rating for AVDL stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate AVDL as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 9 have offered a “buy” rating.
What is AVDL’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $17.00 and a high of $26.00, with their median price target at $18.00. Looking at these predictions, the average price target given by analysts is for Avadel Pharmaceuticals plc ADR (AVDL) stock is $19.89.
